AAAAAA

   
Results: 1-25 |
Results: 25

Authors: Bryskier, A
Citation: A. Bryskier, Anti-anaerobic activity of antibacterial agents, EXPERT OP I, 10(2), 2001, pp. 239-267

Authors: Brandt, CM Honscha, M Truong, ND Holland, R Hovener, B Bryskier, A Lutticken, R Reinert, RR
Citation: Cm. Brandt et al., Microlide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany (vol 7, pg 165, 2001), MICROB DR R, 7(3), 2001, pp. NIL_6-NIL_6

Authors: Brandt, CM Honscha, M Truong, ND Holland, R Hovener, B Bryskier, A Lutticken, R Reinert, RR
Citation: Cm. Brandt et al., Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany, MICROB DR R, 7(2), 2001, pp. 165-170

Authors: Williams, JD Naber, KG Bryskier, A Hoiby, N Gould, IM Periti, P Giamarellou, H Rouveix, B
Citation: Jd. Williams et al., Classification of oral cephalosporins. A matter for debate, INT J ANT A, 17(6), 2001, pp. 443-450

Authors: Lascols, C Bryskier, A Soussy, CJ Tankovic, J
Citation: C. Lascols et al., Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin, J ANTIMICRO, 48(5), 2001, pp. 738-740

Authors: Nagai, K Davies, TA Ednie, LM Bryskier, A Palavecino, E Jacobs, MR Appelbaum, PC
Citation: K. Nagai et al., Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S-pyogenes, ANTIM AG CH, 45(11), 2001, pp. 3242-3245

Authors: Bryskier, A
Citation: A. Bryskier, Perfecting the ring and extending the antibacterial spectrum: 'the multiple generations', CL MICRO IN, 6, 2000, pp. 13-21

Authors: Acar, J Baquero, F Geddes, A Paradisi, F Phillips, I Bryskier, A Low, D Craig, W Levy, S Livermore, D Roberts, D
Citation: J. Acar et al., Roundtable discussion: Cephalosporins in the 1990s and beyond, CL MICRO IN, 6, 2000, pp. 107-111

Authors: Bryskier, A
Citation: A. Bryskier, Ketolides - telithromycin, an example of a new class of antibacterial agents, CL MICRO IN, 6(12), 2000, pp. 661-669

Authors: Bryskier, A
Citation: A. Bryskier, Novelties in the field of anti-infective compounds in 1999, CLIN INF D, 31(6), 2000, pp. 1423-1466

Authors: Joly-Guillou, ML Wolff, M Farinotti, R Bryskier, A Carbon, C
Citation: Ml. Joly-guillou et al., In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia, J ANTIMICRO, 46(5), 2000, pp. 827-830

Authors: Rastogi, N Goh, KS Berchel, M Bryskier, A
Citation: N. Rastogi et al., Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M-bovis BCG, J ANTIMICRO, 46(4), 2000, pp. 565-570

Authors: Bemer-Melchior, P Bryskier, A Drugeon, HB
Citation: P. Bemer-melchior et al., Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex, J ANTIMICRO, 46(4), 2000, pp. 571-575

Authors: Bebear, CM Renaudin, H Bryskier, A Bebear, C
Citation: Cm. Bebear et al., Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas, ANTIM AG CH, 44(7), 2000, pp. 1980-1982

Authors: Rolain, JM Maurin, M Bryskier, A Raoult, D
Citation: Jm. Rolain et al., In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis, ANTIM AG CH, 44(5), 2000, pp. 1391-1393

Authors: Vazifeh, D Bryskier, A Labro, MT
Citation: D. Vazifeh et al., Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils, ANTIM AG CH, 44(3), 2000, pp. 511-521

Authors: Bemer-Melchior, P Juvin, ME Tassin, S Bryskier, A Schito, GC Drugeon, HB
Citation: P. Bemer-melchior et al., In vitro activity of the new ketolide telithromycin compared with those ofmacrolides against Streptococcus pyogenes: Influences of resistance mechanisms and methodological factors, ANTIM AG CH, 44(11), 2000, pp. 2999-3002

Authors: Rastogi, N Goh, KS Berchel, M Bryskier, A
Citation: N. Rastogi et al., In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004compared to those of clarithromycin against slowly growing mycobacteria atpHs 6.8 and 7.4, ANTIM AG CH, 44(10), 2000, pp. 2848-2852

Authors: Bryskier, A
Citation: A. Bryskier, Cephems: Fifty years of continuous research, J ANTIBIOT, 53(10), 2000, pp. 1028-1037

Authors: Bryskier, A
Citation: A. Bryskier, Novelties in the field of anti-infectives in 1998, CLIN INF D, 29(3), 1999, pp. 632-658

Authors: Bergogne-Berezin, E Bryskier, A
Citation: E. Bergogne-berezin et A. Bryskier, The suppository form of antibiotic administration: pharmacokinetics and clinical application, J ANTIMICRO, 43(2), 1999, pp. 177-185

Authors: Fernandez-Roblas, R Calvo, R Esteban, J Bryskier, A Soriano, F
Citation: R. Fernandez-roblas et al., The bactericidal activities of HMR 3004, HMR 3647 and erythromycin againstGram-positive bacilli and development of resistance, J ANTIMICRO, 43(2), 1999, pp. 285-289

Authors: Vazifeh, D Bryskier, A Labro, MT
Citation: D. Vazifeh et al., Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils, ANTIM AG CH, 43(2), 1999, pp. 246-252

Authors: Soriano, F Fernandez-Roblas, R Calvo, R Garcia-Calvo, G Pardeiro, M Bryskier, A
Citation: F. Soriano et al., In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens, J ANTIMICRO, 42(5), 1998, pp. 647-649

Authors: Araujo, FG Khan, AA Bryskier, A Remington, JS
Citation: Fg. Araujo et al., Use of ketolides in combination with other drugs to treat experimental toxoplasmosis, J ANTIMICRO, 42(5), 1998, pp. 665-667
Risultati: 1-25 |